StocksMedium•30 September 2026•
1 min read
Immunome Receives FDA Clearance for IM-1340 Cancer Therapy Clinical Trials
Key Facts
1The U.S. Food and Drug Administration (FDA) cleared Immunome's Investigational New Drug (IND) application for IM-1340.
The U.S. Food and Drug Administration (FDA) cleared Immunome's Investigational New Drug application for IM-1340. Business Wire reported that the clearance allows the company to proceed with clinical trials for the antibody-drug conjugate, which targets advanced solid tumors.
IMNM closed at $21.89 on September 29, 2026, with the stock reaching a day high of $22.01 and a low of $21.36 during that session. This regulatory milestone enables the company to transition into human clinical testing for its oncology treatment pipeline.